As IDO inhibitors are currently in clinical trials for different cancer types including bladder cancer, endometrial cancer or head and neck squamous cell carcinoma (174) it would be of great interest to characterize the immune cell repertoire in the TME upon IDO inhibition. The gene discussed is IDO1; the disease is endometrial cancer.